Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Allodynia: A COMPEL Subanalysis

被引：0
作者：
Young, William B. [1 ]
Rothrock, John F. [2 ]
Lopez, J. Ivan [3 ]
Adams, Aubrey Manack [4 ]
Blumenfeld, Andrew M. [5 ]
机构：
[1] Jefferson Hosp Neurosci, Philadelphia, PA USA
[2] George Washington Sch Med, Washington, DC USA
[3] Univ South Alabama, Coll Med, Mobile, AL 36688 USA
[4] Allergan Plc, Irvine, CA USA
[5] Headache Ctr Southern Calif, Neurol Ctr, Carlsbad, CA USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P4.133
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study
    Rothrock, J. F.
    Luo, L.
    Eross, E. J.
    Sommer, K.
    Blumenfeld, A. M.
    HEADACHE, 2020, 60 : 93 - 93
  • [22] EFFICACY AND SAFETY OF ONABOTULINUMTOXINA IN AN OPEN-LABEL STUDY FOR THE PROPHYLACTIC TREATMENT OF CHRONIC MIGRAINE IN ADULT PATIENTS: COMPEL
    Blumenfeld, A.
    Stark, R.
    Adams, A. Manack
    Orejudos, A.
    Aurora, S.
    CEPHALALGIA, 2016, 36 : 27 - 28
  • [23] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
  • [24] Cognition, disability and quality of life of patients with chronic migraine
    Pompili, M.
    Corigliano, V.
    Denise, E.
    Migliorati, M.
    Martelletti, P.
    Girardi, P.
    EUROPEAN PSYCHIATRY, 2017, 41 : S501 - S501
  • [25] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
  • [26] Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results From the COMPEL Study
    Blumenfeld, A. M.
    Luo, L.
    Yedigarova, L.
    Lipton, R. B.
    HEADACHE, 2020, 60 : 101 - 101
  • [27] Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study
    Blumenfeld, Andrew
    Luo, Lei
    Yedigarova, Larisa
    Lipton, Richard
    NEUROLOGY, 2020, 94 (15)
  • [28] OnabotulinumtoxinA Treatment Improves Quality of Life in Patients with Chronic Migraine (CM): MSQ Results from PREEMPT
    Silberstein, S. D.
    Varon, S. F.
    Diener, H. -C.
    DeGryse, R. E.
    Turkel, C. C.
    HEADACHE, 2010, 50 : S30 - S31
  • [29] Efficacy, tolerability, and safety of onabotulinumtoxinA treatment for chronic migraine in patients with acute medication overuse: analysis of the PREEMPT and COMPEL trials
    Agosti, R.
    Straube, A.
    Diener, H. C.
    Freeman, M.
    Pascual Gomez, J.
    Seminerio, M.
    Delahaye, L.
    Stark, R. J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [30] OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine
    Lipton, R. B.
    Varon, S. F.
    Grosberg, B.
    McAllister, P. J.
    Freitag, F.
    Aurora, S. K.
    Dodick, D. W.
    Silberstein, S. D.
    Diener, H. C.
    DeGryse, R. E.
    Nolan, M. E.
    Turkel, C. C.
    NEUROLOGY, 2011, 77 (15) : 1465 - 1472
12345